EGFR and non-small cell lung carcinoma: The treatment time with osimertinib was 3 years in the ADAURA trial (10), while treatment duration was 2 years in the ADJUVANT/CTONG1104 trial (11) and in the EVAN trial, a phase 2 randomized study evaluating erlotinib vs. vinorelbine and cisplatin as adjuvant therapy in Chinese patients with EGFR-mutated, stage IIIA NSCLC (as per the 7th edition of the AJCC staging system) (28).